Advertisement
AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow purchase articles
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Get other permissions
Google Scholar
Right arrow Articles by Martin, C. K.
Right arrow Articles by Hagan, J. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, C. K.
Right arrow Articles by Hagan, J. J.
Related Collections
Right arrow Hepatitis
Right arrow Public Health Practice
January 2010, Vol 100, No. 1 | American Journal of Public Health 13-17
© 2010 American Public Health Association
DOI: 10.2105/AJPH.2008.147629


FIELD ACTION REPORTS

New Opportunities for the Management and Therapy of Hepatitis C in Correctional Settings

C. Kent Martin, MD, MPH, FACP, Jeffrey E. Hostetter, MD, MS and John J. Hagan, MD

C. Kent Martin is with Medcenter One Health Systems, Bismarck, ND. Jeffrey E. Hostetter and John J. Hagan are with the North Dakota Department of Corrections and Rehabilitation, Bismarck, and the School of Medicine and Health Sciences, University of North Dakota, Bismarck.

Correspondence: Correspondence should be sent to C. Kent Martin, MD, Medcenter One, 222 N 7th St, Bismark, ND 58501 (e-mail: kentmartin{at}bis.midco.net). Reprints can be ordered at http://www.ajph.org by clicking on the "Reprints/Eprints" link.

Hepatitis C in prison populations is now a major public health problem, and large numbers of correctional facilities have no comprehensive management program, often because of formidable projected costs and tightening budget constraints. The North Dakota Department of Corrections and Rehabilitation has operated a management and therapy program since 2002 using consensus interferon and ribavirin with 45% cost savings. The program has provided excellent sustained viral responses: 54.2% for genotype 1 hepatitis C, 75% for genotypes 2 and 3, and 63.6% overall.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2010 by the American Public Health Association